Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7833520 | Method of using interferon-like protein ZCYTO21(IL-29) to treat hepatitis B The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypept... | 11/16/2010 |
| 7829075 | Method for expanding hematopoietic cells using cytokine zalpha11 ligand Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of ... | 11/09/2010 |
| 7829076 | Method of using interferon-like potein ZCYTO20 (IL-28A) or ZCYTO22(IL-28B) to treat hepatitis B The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class I... | 11/09/2010 |
| 7820156 | Method of treatment using a cytokine able to bind IL-18BP to inhibit the activity of a second cytokine The present invention relates to the use of a cytokine-1, preferably from the IL-1 family more preferably IL-1F7b, or an isoform, mutein, fused protein, functional derivative or fragment thereof capable of binding to IL-18BP or a mutein, fused protein, functional de... | 10/26/2010 |
| 7820155 | Methods of treating cancer comprising administering an interleukin-6 antibody variable region The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists o... | 10/26/2010 |
| 7807142 | Stabilized liquid polypeptide-containing pharmaceutical compositions Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an accep... | 10/05/2010 |
| 7803361 | Therapeutic use of interleukin-2 mutants Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhan... | 09/28/2010 |
| 7799323 | Methods of using IL-31 to treat airway hyper-responsiveness and asthma Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include admini... | 09/21/2010 |
| 7799322 | Use of IL-6 in liver injury The invention relates to the use of IL-6 in liver cirrhosis. ... | 09/21/2010 |
| 7785580 | Modified IL-4 mutein receptor antagonists This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These... | 08/31/2010 |
| 7771714 | Medium comprising chicken leukemia inhibitory factor (LIF) The present invention is to provide a chicken LIF gene. Based on this genetic information, LIF protein derived from the chicken can be stably supplied and it solves the problems of the creation of transgenic chickens in the past. In addition, the present invention p... | 08/10/2010 |
| 7767199 | Compositions of IL-21 produced in prokaryotic hosts The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary stru... | 08/03/2010 |
| 7763242 | Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleuki... | 07/27/2010 |
| 7758853 | IFN-γ production inducing protein (IGIF, IL-18) A protein which induces the IFN-γ production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by ... | 07/20/2010 |
| 7749490 | Mutant IL-10 IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are... | 07/06/2010 |
| 7744864 | Method for identifying a patient at risk of having difficulty in sustaining a pregnancy Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colo... | 06/29/2010 |
| 7744866 | IL-1β binding antibodies and binding fragments thereof An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β bi... | 06/29/2010 |
| 7744865 | IL1-β Binding antibodies and fragments thereof An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 9, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β bind... | 06/29/2010 |
| 7744863 | Method of inducing immune tolerance A method of inhibiting Th1 immune response in a subject in need of such treatment which comprises administering to the subject effective amounts for inhibiting Th1 immune response of an anti-CD3 monoclonal antibody and IL-5 or an analogue or mimetic thereof. ... | 06/29/2010 |
| 7736639 | Method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof Methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides and substitution mutants thereof that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein are disclosed. ... | 06/15/2010 |
| 7736638 | Interleukin-15 antagonist peptide Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is sho... | 06/15/2010 |
| 7731946 | Methods and compositions for modulating T helper (T) cell development and function Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level. ... | 06/08/2010 |
| 7727518 | Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor... | 06/01/2010 |
| 7708985 | Glycosylated IL-7, preparation and uses The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well ... | 05/04/2010 |
| 7704490 | Method for inducing selected useful activities of IL-2 in a patient with peptides from IL-2 The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents. ... | 04/27/2010 |
| 7700088 | Interleukin-9 mutein peptides A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it ... | 04/20/2010 |
| 7666402 | Use of IL-22 for the treatment of conditions of metabolic disorders The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes. ... | 02/23/2010 |
| 7662368 | Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2 The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents. ... | 02/16/2010 |
| 7655223 | Method of using interferon-like protein ZCYTO21 (IL-29) to treat hepatitis C The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypept... | 02/02/2010 |
| 7655222 | Method of using interferon-like protein ZCYTO20 (IL-28A) or ZCYTO22 (IL-28B) to treat hepatitis C The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class I... | 02/02/2010 |
| 7645445 | Purified mammalian cytokine IL-174 polypeptides CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided. ... | 01/12/2010 |
| 7625553 | Method of treating cancer by administering an epithelum-derived T-cell factor Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating o... | 12/01/2009 |
| 7611699 | Methods of using cytokine zalpha11 ligand Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of ... | 11/03/2009 |
| 7595039 | Methods of healing wounds by administering human IL-18 The present invention relates generally to the use of human IL-18, also known as interferon-γ-inducing factor (IGIF), in the treatment of skin wounds, surgical wounds, leg ulcers, diabetic ulcers, gastrointestinal mucositis, oral mucositis, and lung injury. ... | 09/29/2009 |
| 7575741 | Methods of treating cutaneous ulcers and grafts using IL-23 Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule. ... | 08/18/2009 |
| 7572436 | Thionin as an antineoplastic and immunostimulant The invention involves cellular and biological responses to relatively low concentrations of thionin (such as Pyrularia thionin), which responses are distinct from the direct cytotoxic effect of high concentrations of thionins on cells. These two separate bio... | 08/11/2009 |
| 7569215 | Mutant interleukin-2 (IL-2) polypeptides The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using... | 08/04/2009 |
| 7531166 | IL-1β binding antibodies and fragments thereof An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an... | 05/12/2009 |
| 7524488 | Interleukin-18 mutants The invention provides mutants of IL-18 with lower affinity to IL-18BP than the wild type IL-18 molecule. ... | 04/28/2009 |
| 7514073 | Therapeutic use of interleukin-2 mutants Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhan... | 04/07/2009 |
